BOHR Journal of Pharmaceutical Studies
2025, Vol. 3, No. 1, pp. 32–38
DOI: 10.54646/BJOPS.2025.17
www.bohrpub.com

REVIEW

Advanced analytical paradigms for cancer nanoparticles: integrative, translational, and regulatory-ready methodologies

Anuprincy Paulmurugan[1]*, Rethina Karuppiahya[2], S. Pranav Ragavendra[3] and Boopathy Palanisamy[3]

[1]Department of Pharmaceutical Analysis, The Erode College of Pharmacy, Erode, India
[2]Department of Pharmaceutical Chemistry, Periyar College of Pharmaceutical Sciences, Tiruchirappalli, India
[3]Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, India

***Correspondence:**
Anuprincy Paulmurugan,
princyanu18@gmail.com

Received: 09 September 2025; **Accepted:** 03 October 2025; **Published:** 28 October 2025

Cancer nanotechnology has developed into a tremendous and tough area of research that will require significant understanding and knowledge to be achieved. Currently, the high number of anti-cancer drugs in nanoparticle research still fail during animal or early stages of clinical studies. This is now becoming the trend due to the lack of the appropriate perspective despite the existence of the biological dynamic system that has governed the interaction of the nanomolecules in the body. This paper therefore differs from the norm since it is presenting an in-depth evaluation regarding the factors to consider during the research on the evaluation of cancer nanomolecules. By combining strategies about what nanoparticles are like, how they react with cell surfaces, what they do in cells, how they function in live biological systems, and how they are evaluated with quality checks, this paper develops a guessable strategy for evaluating them. Unlike other reviews, this one presents the analysis techniques as tools that can help improve formulas, reduce the chance of human failure, and get ready for a change in regulators' perceptions of these novel treatments. The paper looks at recent trends and new patents to show how difficult this analysis can be. Future researchers who want to develop useful cancer nanoparticle platforms can use this work as a guide.

Keywords: cancer nanoparticles, analytical paradigms, translational, methodologies, advanced analysis

Introduction: the analytical bottleneck in cancer nanomedicine

From tiny lipid carriers to more sophisticated organic and hybrid systems, nanotechnology for cancer has more options than ever in the past 20 years. Despite their theoretical potential, such as improved medication accumulation in tumors, regulated release, and fewer side effects, few of these technologies have made it from the lab to the clinic. Few cancer treatments using nanoparticles have completed early-stage trials. Numerous recent studies argue that the gap in the implementation of nanomedicine from research to patients is caused by simple viewpoints (1). Cancer nanomedicine operates inside complex biological systems that involve proteins, immunological responses, physical obstacles, and tumor variety, whereas conventional methods focus on antiquated, static properties in artificial environments. Because of this, many innovative ideas show a gap when evaluated using traditional measures, with laboratory success failing to provide real-world results (2, 3).

Conceptual novelty: analytics as a translational decision architecture

From descriptive characterization to predictive analytics

The essential novel strategy here is that analytical evaluations should operate as a decision-making process rather than merely a data collection process (3).

In high-level nanoparticle work, analytical results need to answer translational questions like:

1. Will this nanoparticle be in the estimated particle size and surface charge ?
2. Will it get through targeted tumor tissue?
3. Will this nanoparticle system evade opsonization?
4. Will it stay consistent in large-scale production?

Every analytical method, then, becomes predictive and helps spot trouble early, allowing smart redesign.

This structured mapping shown in **Table 1** is rarely presented in existing literature and forms a **core originality** of this review (4).

Advanced physicochemical analytics: interpreting beyond size and charge

Particle size as a dynamic, environment-dependent parameter

The advanced information indicates that the size of the nanoparticle is not a static parameter. The size determined through light scattering represents how they behave in water with minimal particles, as illustrated in **Figure 1**, but within the biological system, their size varies due to protein layer formation, flow stress, and salt concentration. In the detailed examination, the size of the nanoparticle must be validated in serum and flow. Variations in native and biological size data often serve as indicators of their rapid clearance or accumulation. Thus, size data is an early marker of nanoparticle instability *in vivo* (4–6).

The light from the laser hits the particles and scatters in all directions, causing them to move randomly in the liquid. As they move, the scattered light changes with time. A detector measures the scattered light at a specific angle to the laser beam. The variations in light over time are sent to a correlator and a computer program that graphs the light change vs. time. From the graph, the computer calculates the speed of the particles. The computer then uses the Stokes-Einstein law to calculate the particle sizes and the area they cover.

Surface charge and biological identity transformation

Zeta potential is no longer a reliable indicator of colloid stability; instead, the behavior of particles in vivo is determined by the changes in surface charge that occur when proteins adsorb onto particles. As a result, the best approach is to examine both the zeta potential and the corona's specific makeup, which shows how particles take on a new biological identity after injection. Cell recognition, immune activation, and particle fate are determined by this biological identity rather than the particle surface itself. Predictions of therapeutic efficacy are frequently erroneous in literature that ignores this shift (6, 7).

Morphology as a manufacturability and penetration determinant

Two observations are necessary for morphological analysis: repeatability and biology. Although they may exhibit better cell uptake in vitro, nonuniform or polymorphic nanoparticles are usually not scalable or consistent across production runs. High-magnification morphological analysis is essential for translational success since it is closely related to process robustness (8–10).

Structural and chemical analytics: stability-informed design

Drug physical state as a release and stability modulator

Figure 2 shows how correlation with rapid stabilization and extended release performance is necessary for enhanced crystallinity data analysis. Amorphous drug dispersion increases solubility, but it also increases the risk of recrystallization during storage or flow. Data from stress testing must be matched with X-ray diffraction (XRD) and differential scanning calorimetry (DSC) measurements in order to determine genuine formulation stability (11, 12).

A fine X-ray beam is shot at a sample of nanocrystals. When the beam hits the atoms in the crystal, it interacts with the many layers of atoms. This causes the beam to spread out in specific directions, forming a diffraction pattern on the detector. The pattern shows the ordered arrangement of atoms, which gives information about the nanocrystals' structure, what type of crystalline phase they are, and how big the smaller crystals or crystallites are. This helps scientists learn about the structure of the material at the smallest scale and recognize the material properties.

TABLE 1 | Stage-integrated analytical mapping (4).

Development phase	Dominant risk	Required Analytical depth	Translational decision
Formulation engineering	Structural instability	Physicochemical + interfacial	Redesign vs. progress
Biological screening	False efficacy	Mechanistic cellular analytics	Optimization
In vivo evaluation	Biodistribution failure	Systems PK & imaging	Go / No-Go
Preclinical translation	Regulatory rejection	QC & reproducibility analytics	IND readiness



FIGURE 1 | Principle of dynamic light scattering (DLS)/photon correlation spectroscopy (PCS).



FIGURE 2 | Method principle for X-ray diffraction (XRD) analysis of nanoparticles.



FIGURE 3 | Principle of nuclear magnetic resonance (NMR) spectroscopy and its relevance to nanoparticle analysis.

Molecular interaction analytics as degradation predictors

An early breakdown is indicated by a chemical contact indicator. Near the failure point, a slight change in fourier transform infrared spectroscopy (FTIR) or nuclear magnetic resonance (NMR) may be visible. This information aids in early mix adjustments to reduce the likelihood of late failure for older users. NMR is shown in **Figure 3**. Spin is present in nuclei with odd protons or neutrons. They align either with (alpha) or against (beta) a strong magnetic field. An energy gap is created as a result. The nuclei absorb and transition to a higher state when radio waves are sent at the proper energy. They emit radio waves that can be interpreted as an NMR spectrum when they fall back. NMR is a great tool for small particles. It helps with figuring out how rings, chains, or medications are arranged on particles. Making sure the ligands are positioned correctly and the surface is functionalized Analyzing how medications attach to particles Observing the dispersion of molecules into larger particles NMR provides fine-grained information at the molecular level (13).

Nuclei with natural spin orient in a magnetic field. They group at a low energy level (alpha state) and a high energy level (beta state). When there is a change in levels of spins, they emit or absorb energy of radiofrequency. This creates signals used in NMR spectroscopy. In nanomolecular systems, NMR helps understand how molecules are shaped and how the surfaces are coated or how drugs attach to polymers or ligands at the nanoscale.

Drug loading and encapsulation

A nanoparticle's drug loading must be sufficient for a therapeutic activity but not greater than the permitted limit for human utilization. Nanomolecule engineering needs to be done very carefully because an excess of carrier material will trigger immune recognition and alter biodistribution patterns. On the other hand, inadequate encapsulation could lead to drug loss during production and a higher requirement for purification downstream. As a result, it is essential to take a note on optimizing drugs, polymers, and other excipients using advanced methods like design of experiments (DoE) (14–17).

In vitro release analytics: toward *in vivo* predictability

Acidic pH, enzymatic activity, and oxidative environments are a few examples of the stimuli examined by *in vitro* drug release testing under biorelevant conditions. The following pH levels should be tested: 5.8, 6.8, and 7.4 Particularly in cancer or specific site targeting. The purpose of such a study is to both mimic a clinical dosing regimen and characterize the release profile (18–22).

Advanced targeting analytics

The existence of biotin, transferrin, and folic acid ligands must be experimentally proven. The conjugation of ligands must be confirmed using FTIR studies; NMR and mass

spectroscopy can also be included. Additionally, surface morphological estimation can be done using scanning electron microscopy (SEM) and transmission electron microscopy (TEM) analysis. Receptor ligand binding kinetics, competitive assays, and structural visualization techniques are used to demonstrate functionality. These techniques differentiate between physiologically functional, targeted nanoparticle products and chemical nanoparticle entities (23–26).

Mechanistic *in vitro* analytics: decoding cellular fate

Mechanistic in vitro analytical approaches are increasingly used to decode cellular fate by evaluating uptake pathways, endosomal escape, apoptotic signaling, and resistance modulation. These strategies provide deeper insight into intracellular drug behavior and translational potential (**Table 2**) (27–30).

In vivo systems analytics: bridging efficacy and safety

Pharmacokinetics, biodistribution, and imaging are currently being combined into a single system format in *in vivo* studies. The temporal and spatial trajectories of nanoparticle transit are determined by live imaging. Information on the toxicity of particular organ uptakes is also being gathered using histopathological estimations along with tissue distribution studies, which will confirm the drug distribution data. Confocal microscopy and flow cytometric analysis are mandatory to confirm the cell cycle phase inhibition and differentiation. To make translational decisions easier, a system overview is required (31, 32).

Recent clinical directions: analytical lessons from current trials

These trends discussed in **Table 3** confirm that analytical maturity, not platform novelty, determines clinical advancement (33–38).

TABLE 2 | Advanced in vitro analytical endpoints and translational significance.

Analytical endpoint	Method	Translational relevance
Uptake pathway mapping	Inhibitor-assisted flow cytometry	Predicts intracellular trafficking
Endosomal escape	pH-sensitive probes	Determines cytosolic drug availability
Apoptotic mechanism	Multiparametric assays	Distinguishes cytostatic vs. cytotoxic effects
Resistance modulation	Gene/protein expression	Predicts long-term efficacy

TABLE 3 | Translational trends in recent cancer nanoparticle trials.

Platform	Clinical focus	Key analytical lesson
Lipid nanoparticles	Cancer vaccines	Immune potency assays critical
Polymeric nanoparticles	Combination chemotherapy	Reproducible drug ratio analytics
Inorganic nanoparticles	Theranostics	Long-term biodistribution essential
Hybrid systems	Multimodal therapy	Cross-platform QC challenges

TABLE 4 | Patent-driven analytical priorities in cancer nanoparticles.

Patent focus	Analytical requirement
Combination nanoparticles	Precise co-loading quantification
Targeted systems	Ligand density & binding analytics
Theranostic platforms	Imaging–therapy correlation
Scalable polymers	Batch reproducibility metrics

Patent landscape: where analytics enable intellectual property

Patents discussed in **Table 4** increasingly depend on validated analytical claims, reinforcing the strategic value of advanced analytics.

Regulatory ready analytics: aligning with quality-by-design

It is now expected by regulatory authorities that all researchers working with nanoparticles enumerate critical quality attributes directly influencing clinical trial outcomes. This comprehensive analytical technique will be used as an integral part of quality-by-design initiatives to ensure therapeutic benefit, safety, and reproducibility and promote robustness throughout development (39–41).

Conclusion

According to this mini review, the future of cancer nanomedicine will depend more on how we view what we already have than on the development of new nanoparticles. This potent new framework tackles the core problems of translational failure by redefining analytical methodologies as predictive, integrative, and decision-driven. Developing such an analytical approach will be essential to transforming cancer nanoparticles from a scientific novelty into a trustworthy clinical reality.

List of abbreviations

AFM: atomic force microscopy; BBB: blood–brain barrier; CQA: critical quality attribute; DLS: dynamic light scattering; DoE: design of experiments; DSC: differential scanning calorimetry; EMA: European Medicines Agency; EPR: enhanced permeation and retention; FDA: food and drug administration; FITC: fluorescein isothiocyanate; FTIR: fourier transform infrared spectroscopy; HPLC: high-performance liquid chromatography; IND: investigational new drug; IVIVC: in vitro–in vivo correlation; NMR: nuclear magnetic resonance; PCS: photon correlation spectroscopy; PK: pharmacokinetics; QC: quality control; QbD: quality by design; ROS: reactive oxygen species; SEM: scanning electron microscopy; TEM: transmission electron microscopy; XRD: X-ray diffraction

Author contributions

Conceptualization, literature search, manuscript drafting, validation, grammar corrections and final approval were performed by the author.

Acknowledgments

We thank the management of Erode College of Pharmacy, JSS College of Pharmacy, and Periyar College of Pharmaceutical Sciences. Figures were created with BioRender.com. Mendeley Reference Manager assisted in citation management. The authors acknowledge the use of OpenAI and QuillBot to assist in grammar correction, paraphrasing, and improving structural clarity of the manuscript.

Funding

None.

Clinical trial

Not applicable.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. *Nat Rev Mater.* (2016) 1(5):16014. doi: 10.1038/natrevmats.2016.14
2. Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. *Nat Mater.* (2020) 19(5):566–75. doi: 10.1038/s41563-019-0566-2
3. Nichols JW, Bae YH. EPR: evidence and fallacy. *J Control Release.* (2014) 190:451–64. doi: 10.1016/j.jconrel.2014.03.057
4. Bhattacharjee S. DLS and zeta potential – what they are and what they are not? *J Control Release.* (2016) 235:337–51. doi: 10.1016/j.jconrel.2016.06.017
5. Wang J, Mi P, Lin G, Wáng YXJ, Liu G, Chen X. Imaging-guided delivery of RNAi for anticancer treatment. *Adv Drug Deliv Rev.* (2016) 104:44–60. doi: 10.1016/j.addr.2016.01.008
6. Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle uptake: the phagocyte problem. *Nano Today.* (2015) 10(4):487–510. doi: 10.1016/j.nantod.2015.06.006
7. Sun T, Jiang C. Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. *Adv Drug Deliv Rev.* (2023) 196:114773. doi: 10.1016/j.addr.2023.114773
8. Zhu J, Yang H, Cao L, Dai C, Ren J, Liang J, et al. Functionalization of structural materials through electro-blown spinning of ultrathin and transparent silk fibroin ionotronic nanofiber skin. *Nano Today.* (2023) 50:101873. doi: 10.1016/j.nantod.2023.101873
9. Zhang S, Yin L, Wang S, Liu JC, Zhang Y, Wen Y, et al. Ternary rare earth alloy Pt 3– *x* Ir *x* Sc nanoparticles modulate negatively charged Pt via charge transfer to facilitate pH-universal hydrogen evolution. *ACS Nano.* (2023) 17(22):23103–14. doi: 10.1021/acsnano.3c08921
10. Nguyen VP, Jeon I, Yang S, Choi ST. Mesoscale simulation of polymer pyrolysis by coarse-grained molecular dynamics: a parametric study. *ACS Appl Mater Interfaces.* (2023) 15(25):30742–55. doi: 10.1021/acsami.3c04192
11. Ohura K, Nakada Y, Imai T. Bioconversion and P-gp-mediated transport of depot fluphenazine prodrugs after intramuscular injection. *J Pharm Sci.* (2023) 112(7):1975–84. doi: 10.1016/j.xphs.2023.03.018
12. Krishna Kumar NS, Suryanarayanan R. Crystallization propensity of amorphous pharmaceuticals: kinetics and thermodynamics. *Mol Pharm.* (2022) 19(2):472–83. doi: 10.1021/acs.molpharmaceut.1c00839
13. Levit SL, Stwodah RM, Tang C. Rapid, room temperature nanoparticle drying and low-energy reconstitution via electrospinning. *J Pharm Sci.* (2018) 107(3):807–13. doi: 10.1016/j.xphs.2017.10.026
14. Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems. *Polymers (Basel).* (2023) 15(7):1596. doi: 10.3390/polym15071596
15. Kumar M, Kulkarni P, Liu S, Chemuturi N, Shah DK. Nanoparticle biodistribution coefficients: a quantitative approach for understanding the tissue distribution of nanoparticles. *Adv Drug Deliv Rev.* (2023) 194:114708. doi: 10.1016/j.addr.2023.114708
16. Nowak-Jary J, Machnicka B. In vivo biodistribution and clearance of magnetic iron oxide nanoparticles for medical applications. *Int J Nanomedicine.* (2023) 18:4067–100. doi: 10.2147/IJN.S415063
17. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. *Nat Rev Drug Discov.* (2021) 20(2):101–24. doi: 10.1038/s41573-020-0090-8
18. Martínez-Sanz E, Ossipov DA, Hilborn J, Larsson S, Jonsson KB, Varghese OP. Bone reservoir: Injectable hyaluronic acid hydrogel for minimal invasive bone augmentation. *J Control Release.* (2011) 152(2):232–40. doi: 10.1016/j.jconrel.2011.02.003
19. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nat Rev Drug Discov.* (2014) 13(11):813–27. doi: 10.1038/nrd4333

20. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. *Adv Drug Deliv Rev.* (2012) 64:246–55. doi: 10.1016/j.addr.2012.09.022
21. Donoso MD, Haskell RJ, Schartman RR. Surfactant choice and the physical stability of nanosuspensions as a function of pH. *Int J Pharm.* (2012) 439(1–2):1–7. doi: 10.1016/j.ijpharm.2012.09.012
22. Gao M, Ma Y, Cui R, Liu D. Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet. *J Control Release.* (2014) 185:1–11. doi: 10.1016/j.jconrel.2014.03.047
23. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. *Adv Drug Deliv Rev.* (2012) 64:24–36. doi: 10.1016/j.addr.2012.09.006
24. Fukuda M, Ohtani K, Jang SJ, Yoshizaki T, Mori K, Motomura W, et al. Molecular cloning and functional analysis of scavenger receptor zebrafish CL-P1. *Biochim Biophys Acta Gen Subj.* (2011) 1810(12):1150–9. doi: 10.1016/j.bbagen.2011.09.016
25. Murab S, Samal J, Shrivastava A, Ray AR, Pandit A, Ghosh S. Glucosamine loaded injectable silk-in-silk integrated system modulate mechanical properties in bovine ex-vivo degenerated intervertebral disc model. *Biomaterials.* (2015) 55:64–83. doi: 10.1016/j.biomaterials.2015.03.032
26. Lai HM, Liu AKL, Ng HHM, Goldfinger MH, Chau TW, DeFelice J, et al. Clearing the way for imaging of the human brain. *Nat Methods.* (2018) 15(5):313. doi: 10.1038/nmeth.4669
27. Kim D, Lee ES, Park K, Kwon IC, Bae YH. Doxorubicin Loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor. *Pharm Res.* (2008) 25(9):2074. doi: 10.1007/s11095-008-9603-6
28. Ling D, Park W, Park SJ, Lu Y, Kim KS, Hackett MJ, et al. Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. *J Am Chem Soc.* (2014) 136(15):5647–55. doi: 10.1021/ja4108287
29. Hassan M, Farid D, Mahdi A, Masood K, Hossein A, Morteza K. Methotrexate-loaded PLGA nanoparticles: preparation, characterization and their cytotoxicity effect on human glioblastoma U87MG cells. *Int J Med Nano Res.* (2017) 4(1):020. doi: 10.23937/2378-3664/1410020
30. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. *N Engl J Med.* (2011) 365(18):1673–83. doi: 10.1056/NEJMoa1106152
31. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. *Bioeng Transl Med* (2019) 4(3):10143. doi: 10.1002/btm2.10143
32. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. *Nat Nanotechnol.* (2007) 2(8):469–78. doi: 10.1038/nnano.2007.223
33. Roy R, Sankar V, Ragavendra P. Formulation development, optimization and evaluation of imipramine loaded nano-structured lipid carrier. *J Young Pharm.* (2024) 16(3):547–55. doi: 10.5530/jyp.2024.16.68
34. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. *Mol Ther.* (2017) 25(7):1467–75. doi: 10.1016/j.ymthe.2017.03.013
35. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. *J Drug Target.* (2008) 16(2):108–23. doi: 10.1080/10611860701794353
36. Zavaleta C, Ho D, Chung EJ. Theranostic nanoparticles for tracking and monitoring disease state. *SLAS Technol.* (2018) 23(3):281–93. doi: 10.1177/2472630317738699
37. Xin J, Deng C, Aras O, Zhou M, Wu C, An F. Chemodynamic nanomaterials for cancer theranostics. *J Nanobiotechnol.* (2021) 19(1):192. doi: 10.1186/s12951-021-00936-y
38. Zielińska D, Siwińska-Ciesielczyk K, Bula K, Jesionowski T, Borysiak S. TiO_2/nanocellulose hybrids as functional additives for advanced polypropylene nanocomposites. *Ind Crops Prod.* (2022) 176:114314. doi: 10.1016/j.indcrop.2021.114314
39. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, et al. Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs). *AAPS PharmSciTech.* (2009) 10(4):1276–85. doi: 10.1208/s12249-009-9312-4
40. Alemie AA, Siraj EA, Yayehrad AT, Tafere C, Tessema TA, Belete A. Continuous pharmaceutical manufacturing and its contemporary regulatory insights. *Discover Appl Sci.* (2025) 7(10):1057. doi: 10.1007/s42452-025-07712-9
41. Hwang J, Lee S, Jeon S, Cho H, Lee J, Kim E. Innovative technological emerging platform: exploring PROTAC research and regulatory trends. *Yakhak Hoeji.* (2025) 69(4):319–27. doi: 10.17480/psk.2025.69.4.319